QC
TEVA icon

Quadrature Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Quadrature Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-116,643
Closed -$2.36M – 1644
2025
Q3 		$2.36M Sell
116,643
-44,857
-28% -$788K 0.03% 272
2025
Q2 		$2.7M Buy
+161,500
New +$2.61M 0.05% 251
2025
Q1 		– Sell
-77,930
Closed -$1.72M – 1466
2024
Q4 		$1.72M Sell
77,930
-90,093
-54% -$1.64M 0.03% 328
2024
Q3 		$3.03M Sell
168,023
-249,837
-60% -$4.37M 0.07% 201
2024
Q2 		$6.79M Buy
417,860
+325,858
+354% +$5.02M 0.11% 156
2024
Q1 		$1.3M Buy
92,002
+72,555
+373% +$915K 0.02% 409
2023
Q4 		$203K Buy
+19,447
New +$182K ﹤0.01% 981
2022
Q3 		– Sell
-27,308
Closed -$205K – 1087
2022
Q2 		$205K Sell
27,308
-55,444
-67% -$483K 0.01% 623
2022
Q1 		$776K Buy
+82,752
New +$691K 0.03% 306
2021
Q3 		– Sell
-99,112
Closed -$982K – 1029
2021
Q2 		$982K Sell
99,112
-38,655
-28% -$409K 0.04% 316
2021
Q1 		$1.59M Buy
137,767
+120,667
+706% +$1.38M 0.08% 221
2020
Q4 		$165K Buy
+17,100
New +$164K 0.01% 742
2020
Q3 		– Sell
-165,931
Closed -$2.04M – 909
2020
Q2 		$2.04M Buy
165,931
+56,724
+52% +$642K 0.23% 133
2020
Q1 		$980K Sell
109,207
-381,610
-78% -$3.91M 0.23% 125
2019
Q4 		$4.81M Sell
490,817
-461,550
-48% -$4.12M 0.18% 133
2019
Q3 		$6.56M Buy
952,367
+491,798
+107% +$3.77M 0.32% 94
2019
Q2 		$4.24M Buy
460,569
+434,945
+1,697% +$5.24M 0.28% 95
2019
Q1 		$402K Buy
+25,624
New +$452K 0.03% 368
2018
Q1 		– Sell
-30,102
Closed -$571K – 752
2017
Q4 		$571K Sell
30,102
-113,010
-79% -$1.7M 0.05% 309
2017
Q3 		$2.52M Buy
+143,112
New +$3.22M 0.32% 82
2017
Q2 		– Sell
-48,852
Closed -$1.57M – 769
2017
Q1 		$1.57M Buy
48,852
+30,452
+166% +$1.04M 0.11% 203
2016
Q4 		$668K Sell
18,400
-340,317
-95% -$13.6M 0.02% 508
2016
Q3 		$16.5M Buy
358,717
+263,869
+278% +$13.8M 1.44% 10
2016
Q2 		$4.76M Buy
94,848
+49,467
+109% +$2.63M 0.35% 73
2016
Q1 		$2.43M Buy
+45,381
New +$2.66M 0.34% 82
2015
Q4 		– Sell
-29,610
Closed -$1.67M – 523
2015
Q3 		$1.67M Buy
+29,610
New +$1.92M 0.56% 54
2015
Q2 		– Sell
-11,125
Closed -$693K – 204
2015
Q1 		$693K Buy
+11,125
New +$647K 1.01% 35

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Quadrature Capital's TEVA Position: Q4 2025 in Review

Quadrature Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 116,643 shares — an estimated $2.36M sold.

Quadrature Capital first reported a position in TEVA in Q1 2015 and held it in 27 quarters. The position peaked at $16.5M in Q3 2016. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Quadrature Capital reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 116,643 Teva Pharmaceuticals shares in Q4 2025, an estimated $2.36M.
  • Quadrature Capital first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 27 quarters.
  • Quadrature Capital's Teva Pharmaceuticals position peaked at $16.5M in Q3 2016.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.